{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:31:31Z","timestamp":1785843091671,"version":"3.56.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>In Marfan syndrome (MFS), dilation, dissection, and rupture of the aorta occur. Inflammation can be involved in the pathogenicity of aortic defects and can thus be a therapeutic target for MFS. Previously, we showed that the formulation of methotrexate (MTX) associated with lipid nanoparticles (LDE) has potent anti-inflammatory effects without toxicity. To investigate whether LDEMTX treatment can prevent the development of aortic lesions in the MFS murine model. Mg\u0394loxPneo MFS (<jats:italic>n<\/jats:italic> = 40) and wild-type (WT, <jats:italic>n<\/jats:italic> = 60) mice were allocated to 6 groups weekly injected with IP solutions of: (1) only LDE; (2) commercial MTX; (3) LDEMTX (dose = 1mg\/kg) between 3rd and 6th months of life. After 12 weeks of treatments, animals were examined by echocardiography and euthanatized for morphometric and molecular studies. MFS mice treated with LDEMTX showed narrower lumens in the aortic arch, as well as in the ascending and descending aorta. LDEMTX reduced fibrosis and the number of dissections in MFS but not the number of elastic fiber disruptions. In MFS mice, LDEMTX treatment lowered protein expression of pro-inflammatory factors macrophages (CD68), T-lymphocytes (CD3), tumor necrosis factor-\u03b1 (TNF-\u03b1), apoptotic factor cleaved-caspase 3, and type 1 collagen and lowered the protein expression of the transforming growth factor-\u03b2 (TGF-\u03b2), extracellular signal-regulated kinases \u00bd (ERK1\/2), and SMAD3. Protein expression of CD68 and CD3 had a positive correlation with an area of aortic lumen (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup> = 0.36; <jats:italic>p<\/jats:italic> &amp;lt; 0.001), suggesting the importance of inflammation in the causative mechanisms of aortic dilation. Enhanced adenosine availability by LDEMTX was suggested by higher aortic expression of an anti-adenosine A2a receptor (A2a) and lower adenosine deaminase expression. Commercial MTX had negligible effects. LDEMTX prevented the development of MFS-associated aortic defects and can thus be a candidate for testing in clinical studies.<\/jats:p>","DOI":"10.3389\/fcvm.2022.893774","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:47:43Z","timestamp":1654840063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment With Methotrexate Associated With Lipid Core Nanoparticles Prevents Aortic Dilation in a Murine Model of Marfan Syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Maria Carolina","family":"Guido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia de Menezes","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Inagaki","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Rufo","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila de Oliveira","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thauany Martins","family":"Tavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Ribeiro","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lygia da Veiga","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Rafael Martins","family":"Laurindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Cavalcante","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/S0140-6736(05)66995-4","article-title":"Marfan's syndrome","volume":"366","author":"Ho","year":"2005","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1161\/CIRCULATIONAHA.107.693523","article-title":"Medical management of Marfan syndrome","volume":"117","author":"Keane","year":"2008","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.arr.2009.09.001","article-title":"Recent molecular biological progress in Marfan syndrome and Marfan-associated disorders","volume":"9","author":"Gao","year":"2010","journal-title":"Ageing Res Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.3892\/mmr.2017.7544","article-title":"A novel FBN1 mutation causes autosomal dominant Marfan syndrome","volume":"16","author":"Xiao","year":"2017","journal-title":"Mol Med Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJM199007193230303","article-title":"Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome","volume":"323","author":"Hollister","year":"1990","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0070-2153(06)75004-9","article-title":"Fibrillins: from biogenesis of microfibrils to signaling functions","volume":"75","author":"Hubmacher","year":"2006","journal-title":"Curr Top Dev Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1074\/jbc.M209256200","article-title":"Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein","volume":"278","author":"Isogai","year":"2003","journal-title":"J Biol Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.200608167","article-title":"Fibrillin-1 regulates the bioavailability of TGFbeta1","volume":"176","author":"Chaudhry","year":"2007","journal-title":"J Cell Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5603\/CJ.2013.0066","article-title":"The role of transforming growth factor-beta in Marfan syndrome","volume":"20","author":"Benke","year":"2013","journal-title":"Cardiol J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/ijms19072125","article-title":"TGF-beta Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections","volume":"19","author":"Takeda","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1086\/521409","article-title":"Marfan Syndrome: From Molecules to Medicines","volume":"81","author":"Dietz","year":"2007","journal-title":"Am J Hum Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mgene.2013.10.008","article-title":"Marfan syndrome: an eyesight of syndrome","volume":"2","author":"Kumar","year":"2014","journal-title":"Meta Gene."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2015.05.072","article-title":"Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome","volume":"194","author":"Franken","year":"2015","journal-title":"Int J Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0164778","DOI":"10.1371\/journal.pone.0164778","article-title":"Aortic and Cardiac Structure and Function Using High-Resolution Echocardiography and Optical Coherence Tomography in a Mouse Model of Marfan Syndrome","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.carpath.2018.01.005","article-title":"Pathogenesis of aortic wall complications in Marfan syndrome","volume":"33","author":"Grewal","year":"2018","journal-title":"Cardiovasc Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/hq0701.092136","article-title":"Aortic wall mechanics and composition in a transgenic mouse model of Marfan syndrome","volume":"21","author":"Marque","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jbiomech.2015.11.059","article-title":"Differential ascending and descending aortic mechanics parallel aneurysmal propensity in a mouse model of Marfan syndrome","volume":"49","author":"Bellini","year":"2016","journal-title":"J Biomech."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e32963","DOI":"10.1371\/journal.pone.0032963","article-title":"Inflammation aggravates disease severity in Marfan syndrome patients","volume":"7","author":"Radonic","year":"2012","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00059-019-4786-7","article-title":"Inflammation in thoracic aortic aneurysms","volume":"44","author":"Dinesh","year":"2019","journal-title":"Herz."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/art.40870","article-title":"Derivation and validation of a major toxicity risk score among nonsteroidal antiinflammatory drug users based on data from a randomized controlled trial","volume":"71","author":"Solomon","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.18433\/J3VW2F","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh","year":"2013","journal-title":"J Pharm Pharm Sci."},{"key":"B23","first-page":"1003","article-title":"Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease","volume":"25","author":"Maranh\u00e3o","year":"1992","journal-title":"Braz J Med Biol Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/BF02535988","article-title":"Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein","volume":"28","author":"Maranh\u00e3o","year":"1993","journal-title":"Lipids."},{"key":"B25","first-page":"4660","article-title":"Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia","volume":"54","author":"Maranh\u00e3o","year":"1994","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s11745-997-0080-6","article-title":"Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors","volume":"32","author":"Maranh\u00e3o","year":"1997","journal-title":"Lipids."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.V52.6.1099.1099","article-title":"Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells","volume":"52","author":"Ho","year":"1978","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10557-013-6488-3","article-title":"Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits","volume":"27","author":"Bulgarelli","year":"2013","journal-title":"Cardiovasc Drugs Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/IJN.S29392","article-title":"Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis","volume":"8","author":"Mello","year":"2013","journal-title":"Int J Nanomed."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e6225","DOI":"10.1590\/1414-431x20176225","article-title":"Methotrexate associated to lipid core nanoparticles improves cardiac allograft vasculopathy and the inflammatory profile in a rabbit heart graft model","volume":"50","author":"Fiorelli","year":"2017","journal-title":"Braz J Med Biol Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/IJN.S129324","article-title":"Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats","volume":"12","author":"Maranh\u00e3o","year":"2017","journal-title":"Int J Nanomedicine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/lipd.12014","article-title":"The expression of lipoprotein receptors is increased in the infarcted area after myocardial infarction induced in rats with cardiac dysfunction","volume":"53","author":"de Lima","year":"2018","journal-title":"Lipids."},{"key":"B33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1021\/acs.molpharmaceut.1c00794","article-title":"Anti-tumor effect of folate-binding protein: in vitro and in vivo studies","volume":"7","author":"Samadian","year":"2022","journal-title":"Mol Pharm"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e14136","DOI":"10.1371\/journal.pone.0014136","article-title":"A new mouse model for Marfan syndrome presents phenotypic variability associated with the genetic background and overall levels of Fbn1 expression","volume":"5","author":"Lima","year":"2010","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3967213","DOI":"10.1155\/2018\/3967213","article-title":"Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model","volume":"2018","author":"Guido","year":"2018","journal-title":"Oxid Med Cell Longev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/IJN.S18039","article-title":"Novel formulation of a methotrexate derivative with a lipid nanoemulsion","volume":"6","author":"Moura","year":"2011","journal-title":"Int J Nanomedicine."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0224581","DOI":"10.1371\/journal.pone.0224581","article-title":"Association of thoracic spine deformity and cardiovascular disease in a mouse model for Marfan syndrome","volume":"14","author":"de Souza","year":"2019","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ijcard.2010.12.070","article-title":"The Ghent Marfan Trial\u2013a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers","volume":"157","author":"M\u00f6berg","year":"2012","journal-title":"Int J Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","article-title":"Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome","volume":"72","author":"Teixido-Tura","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamacardio.2019.1176","article-title":"Update on clinical trials of losartan with and without beta-blockers to block aneurysm growth in patients with Marfan syndrome: a review","volume":"4","author":"Hofmann Bowman","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.amjcard.2020.04.034","article-title":"Meta-analysis examining the usefulness of angiotensin receptor blockers for the prevention of aortic root dilation in patients with the Marfan syndrome","volume":"128","author":"Al-Abcha","year":"2020","journal-title":"Am J Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e107221","DOI":"10.1371\/journal.pone.0107221","article-title":"No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice","volume":"9","author":"Franken","year":"2014","journal-title":"PLoS ONE."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12945\/j.aorta.2013.13.007","article-title":"Indomethacin prevents the progression of thoracic aortic aneurysm in Marfan syndrome mice","volume":"1","author":"Guo","year":"2013","journal-title":"Aorta."},{"key":"B44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.prostaglandins.2016.05.001","article-title":"Participation of oleic acid in the formation of the aortic aneurysm in Marfan syndrome patients","volume":"123","author":"Soto","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omtn.2017.08.014","article-title":"AP-1 Oligodeoxynucleotides reduce aortic elastolysis in a murine model of Marfan syndrome","volume":"9","author":"Arif","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e000476","DOI":"10.1161\/JAHA.113.000476","article-title":"IL-6 regulates extracellular matrix remodeling associated with aortic dilation in a fibrillin-1 hypomorphic mgR\/mgR mouse model of severe Marfan syndrome","volume":"3","author":"Ju","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.carpath.2018.10.002","article-title":"Renal cystic disease in the Fbn1 (C1039G\/+) Marfan mouse is associated with enhanced aortic aneurysm formation","volume":"38","author":"Hibender","year":"2019","journal-title":"Cardiovasc Pathol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/ATVBAHA.114.304364","article-title":"Enhanced caspase activity contributes to aortic wall remodeling and early aneurysm development in a murine model of Marfan syndrome","volume":"35","author":"Emrich","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/hc37t1.094856","article-title":"Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome","author":"Nagashima","year":"2001"},{"key":"B50","first-page":"645","article-title":"Aortic aneurysm in Marfan's syndrome: changes in the ultrastructure and composition of collagen","volume":"129","author":"Scheck","year":"1979"},{"key":"B51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jsb.2014.07.003","article-title":"Quantification of aortic and cutaneous elastin and collagen morphology in Marfan syndrome by multiphoton microscopy","volume":"187","author":"Cui","year":"2014","journal-title":"J Struct Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/ATVBAHA.114.304412","article-title":"Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome","volume":"35","author":"Crosas-Molist","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCRESAHA.107.157776","article-title":"Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and\u22129 in the thoracic aortic aneurysm in Marfan syndrome","volume":"101","author":"Chung","year":"2007","journal-title":"Circ Res."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.09.016","article-title":"Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome","author":"Xiong","year":"2008","journal-title":"J Vasc Surg"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1161\/CIRCRESAHA.112.268268","article-title":"MMP-2 regulates Erk1\/2 phosphorylation and aortic dilatation in Marfan syndrome","volume":"110","author":"Xiong","year":"2012","journal-title":"Circ Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"165587","DOI":"10.1016\/j.bbadis.2019.165587","article-title":"Impaired vascular smooth muscle cell force-generating capacity and phenotypic deregulation in Marfan Syndrome mice","volume":"1866","author":"Nolasco","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cvr\/cvu196","article-title":"Angiogenesis and remodelling in human thoracic aortic aneurysms","volume":"104","author":"Kessler","year":"2014","journal-title":"Cardiovasc Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.14744\/AnatolJCardiol.2018.42223","article-title":"Neovascularization with chronic inflammation characterizes ascending ortic dissection","volume":"20","author":"Niinim\u00e4k","year":"2018","journal-title":"Anatol J Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.06.002","volume":"140","year":"2013","journal-title":"Pharmacol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1097\/CCM.0b013e318259205b","article-title":"How systemic inflammation modulates adenosine metabolism and adenosine receptor expression in humans in vivo","volume":"40","author":"Ramakers","year":"2012","journal-title":"Crit Care Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2013.00085","article-title":"Regulation of inflammation by adenosine","volume":"4","author":"Hask\u00f3","year":"2013","journal-title":"Front Immunol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.893774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:47:48Z","timestamp":1654840068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.893774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":61,"alternative-id":["10.3389\/fcvm.2022.893774"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.893774","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"article-number":"893774"}}